News
Media
Between the LinesExpert InterviewsK-CastMedical World NewsPodcastsPopulation Health Perspectives
Conferences
Partners
More
Publications
All PublicationsMHE PublicationFormulary Watch SupplementsFormulary Watch SpotlightsSupplements And Featured Publications
Events
Webinars
CME/CE
Resources
PBMI InnovatorsEmerging LeadersInteractive ToolsSponsored Content
PBM Directory

Subscribe

  • News
  • Media
  • Conferences
  • Partners
  • Publications
  • Events
  • CME/CE
  • Resources
  • PBM Directory
  • Subscribe
  • Asthma
  • Atrial Fibrillation
  • Autoimmune Diseases
  • Biologics
  • Biosimilars
  • Blood Cancer
  • Breast Cancer
  • COVID-19
  • Cardiovascular Diseases
  • Depression
  • Dermatology
  • Diabetes
  • Digital Health
  • Drug Coverage
  • Duchenne Muscular Dystrophy
  • Eyecare
  • FDA
  • Friedreich Ataxia
  • Gene Therapy
  • Graft Versus Host Disease
  • HIV
  • Health Systems
  • Heart Failure
  • Hemophilia
  • Hypertrophic Cardiomyopathy (HCM)
  • Infectious Disease
  • Leukemia and Lymphoma
  • Liver Disease
  • Lung Cancer
  • Mental Health
  • Multiple Sclerosis
  • NSCLC
  • Neonatal Care
  • Nephrology
  • Obstetrics-Gynecology & Women's Health
  • Oncology
  • Oncology Biomarkers
  • Opioids
  • PTSD
  • Pain
  • Pediatrics
  • Plaque Psoriasis
  • Population Health
  • Post-Acute Care
  • Prescription Digital Therapeutics
  • Pulmonary Arterial Hypertension
  • RSV
  • Reproductive Health
  • Respiratory Conditions
  • Safety & Recalls
  • Schizophrenia
  • Shingles
  • Skin Cancer
  • Sleep Disorders
  • Solid Tumors
  • Spinal Muscular Atrophy
  • Substance Use Disorder
  • The Improving Patient Access Podcast
  • Type I Diabetes
  • Type II Inflammation
  • Ulcerative Colitis
  • Uro-Oncology
  • Urothelial Carcinoma
  • Vaccines
  • Women's Health
Spotlight -
AAO 2025|
PBMI 2025|
ASRS 2025|
IAS 2025|
K-Cast: Optimizing Narcolepsy Care
Advertisement

Jana Volante Walshak

Advertisement

Articles by Jana Volante Walshak

DOJ Issues Important Updates to Evaluation of Corporate Compliance Guidance

ByOksana G. Wright,Charles A. DeMonaco,Jana Volante Walshak
July 28th 2020

A strong, up-to-date compliance program should be part of a healthcare company's risk management strategy.

Advertisement

Latest Updated Articles

  • DOJ Issues Important Updates to Evaluation of Corporate Compliance Guidance
    DOJ Issues Important Updates to Evaluation of Corporate Compliance Guidance

    Published: July 28th 2020 | Updated:



Advertisement
Advertisement

Trending on Managed Healthcare Executive

1

Medicare Provides Coverage, But Care Depends on Location

2

California PBM Law is a Starting Point for Real Transparency

3

Experts Urge Reclassifying Some Melanoma as Precancer to Prevent Overtreatment

4

Professional Pickleball Players Most Likely to Sustain Eye Injury, Least Likely to Wear Eye Protection, Survey Shows | 2025 AAO

5

Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Formulary Watch
  • Pharmacy Benefit Management Institute
Managed Healthcare Executive
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us